Daewoong Pharma (KO:069620) — Stock Price
Daewoong Pharma (KO:069620) is currently trading at ₩129500.00 KRW, up 0.39% today. Over the past 52 weeks, shares have ranged between ₩107300.00 and ₩194000.00. This page tracks Daewoong Pharma's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see 069620 market cap overview.
Daewoong Pharma (069620) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Daewoong Pharma's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Daewoong Pharma Income Statement — Revenue, Profit & Earnings by Year
Daewoong Pharma's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩1.42 Trillion | ₩1.38 Trillion | ₩1.28 Trillion | ₩1.15 Trillion | ₩1.06 Trillion |
| Cost of Revenue | ₩688.52 Billion | ₩687.16 Billion | ₩641.13 Billion | ₩608.23 Billion | ₩608.48 Billion |
| Gross Profit | ₩734.17 Billion | ₩688.17 Billion | ₩638.96 Billion | ₩544.75 Billion | ₩446.94 Billion |
| Research & Development | ₩171.29 Billion | ₩171.57 Billion | ₩163.60 Billion | ₩127.27 Billion | ₩115.22 Billion |
| SG&A | ₩268.19 Billion | ₩257.00 Billion | ₩245.42 Billion | ₩215.20 Billion | ₩207.75 Billion |
| Total Operating Expenses | ₩1.27 Trillion | ₩1.25 Trillion | ₩1.18 Trillion | ₩1.06 Trillion | ₩1.04 Trillion |
| Operating Income | ₩147.94 Billion | ₩122.59 Billion | ₩95.80 Billion | ₩88.90 Billion | ₩16.98 Billion |
| EBITDA | — | — | ₩86.43 Billion | ₩71.07 Billion | ₩65.05 Billion |
| EBIT | — | — | ₩95.80 Billion | ₩88.73 Billion | ₩16.98 Billion |
| Interest Expense | ₩6.99 Billion | ₩13.60 Billion | ₩8.41 Billion | ₩10.25 Billion | ₩10.61 Billion |
| Income Before Tax | ₩56.55 Billion | ₩122.00 Billion | ₩38.33 Billion | ₩19.93 Billion | ₩13.56 Billion |
| Income Tax Expense | — | — | ₩-833.51 Million | ₩-10.32 Billion | ₩-10.59 Billion |
| Net Income | ₩24.73 Billion | ₩121.74 Billion | ₩42.24 Billion | ₩24.66 Billion | ₩12.75 Billion |
Daewoong Pharma Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Daewoong Pharma's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩1.98 Trillion | ₩1.57 Trillion | ₩1.56 Trillion | ₩1.42 Trillion | ₩1.37 Trillion |
| Total Current Assets | ₩612.79 Billion | ₩392.35 Billion | ₩548.97 Billion | ₩520.40 Billion | ₩528.35 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩13.40 Billion | ₩26.18 Billion | ₩37.70 Billion | ₩97.83 Billion | ₩104.82 Billion |
| Net Receivables | ₩160.74 Billion | ₩137.51 Billion | ₩142.16 Billion | ₩121.59 Billion | ₩118.36 Billion |
| Inventory | ₩256.35 Billion | ₩202.96 Billion | ₩208.74 Billion | ₩170.56 Billion | ₩173.97 Billion |
| Property, Plant & Equipment | — | — | ₩440.89 Billion | ₩395.87 Billion | ₩393.69 Billion |
| Goodwill | ₩60.85 Billion | ₩60.85 Billion | ₩60.85 Billion | ₩60.85 Billion | ₩60.85 Billion |
| Total Liabilities | ₩1.05 Trillion | ₩762.77 Billion | ₩822.12 Billion | ₩712.77 Billion | ₩671.66 Billion |
| Total Current Liabilities | ₩629.42 Billion | ₩695.53 Billion | ₩472.83 Billion | ₩460.66 Billion | ₩326.75 Billion |
| Long-term Debt | ₩324.48 Billion | ₩65.00 Billion | ₩204.84 Billion | ₩181.71 Billion | ₩291.17 Billion |
| Net Debt | ₩543.02 Billion | ₩416.97 Billion | ₩335.56 Billion | ₩361.79 Billion | ₩365.84 Billion |
| Total Stockholder Equity | ₩794.64 Billion | ₩802.97 Billion | ₩608.02 Billion | ₩573.57 Billion | ₩550.99 Billion |
| Retained Earnings | ₩635.67 Billion | ₩647.84 Billion | ₩504.29 Billion | ₩467.36 Billion | ₩452.80 Billion |
Daewoong Pharma Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Daewoong Pharma generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩51.49 Billion | ₩132.57 Billion | ₩118.21 Billion | ₩39.99 Billion | ₩100.98 Billion |
| Capital Expenditures | ₩229.00 Billion | ₩118.67 Billion | ₩65.23 Billion | ₩29.09 Billion | ₩26.49 Billion |
| Free Cash Flow | ₩-177.51 Billion | ₩13.89 Billion | ₩4.91 Billion | ₩-34.80 Billion | ₩41.28 Billion |
| Investing Cash Flow | — | — | ₩-106.87 Billion | ₩-87.68 Billion | ₩-127.15 Billion |
| Financing Cash Flow | — | — | ₩15.52 Billion | ₩50.22 Billion | ₩66.59 Billion |
| Dividends Paid | ₩7.74 Billion | ₩6.64 Billion | ₩8.07 Billion | ₩6.46 Billion | ₩6.19 Billion |
| Stock-Based Compensation | ₩545.31 Million | ₩252.72 Million | ₩1.84 Billion | ₩2.00 Billion | ₩1.19 Billion |
| Depreciation | ₩48.98 Billion | ₩35.66 Billion | ₩39.69 Billion | ₩40.88 Billion | ₩40.88 Billion |
| Change in Cash | ₩-8.56 Billion | ₩-13.77 Billion | ₩27.04 Billion | ₩3.61 Billion | ₩40.21 Billion |
Daewoong Pharma Earnings History — EPS Actual vs. Analyst Estimates
Track Daewoong Pharma's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Apr 27, 2026 | — | — | — |
| Feb 09, 2026 | — | — | — |
| Oct 28, 2025 | 4029.58 | — | — |
| Aug 07, 2025 | 3281.32 | — | — |
| Apr 28, 2025 | 1903.00 | 2329.77 | -18.32% |
| Feb 10, 2025 | -1115.10 | 2375.27 | -146.95% |
| Oct 30, 2024 | 2458.00 | 2341.00 | +5.00% |
| Aug 08, 2024 | 99.00 | 2224.46 | -95.55% |